GE to Sell BioPharma Business to Danaher for $21.4 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Danaher (DHR) PT Raised to $125 at Baird
February 26, 2019 9:15 AM ESTBaird analyst Richard Eastman raised the price target on Danaher (NYSE: DHR) to $125.00 (from $114.00) while maintaining an Outperform rating following the announced GE Biopharma acquisition. Eastman views the acquisition as attractive.
Adjusting for ~$1.4B in NPV tax benefits to DHR, the purchase price... More
